● Recruiting

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Condition: Multiple Myeloma · Sponsor: Carl Ola Landgren, MD, PhD

PhasePhase 2

Planned participants50

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

This description comes directly from the study's public registry record.

Talk to the study team

Michelle Armogan · (305) 243-6578 · mda182@med.miami.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Miami

Miami, Florida, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06100237